Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

[1]  N. Munshi,et al.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis , 2017, JAMA oncology.

[2]  B. Barlogie,et al.  Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma , 2016, Clinical Cancer Research.

[3]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[4]  F. Prósper,et al.  Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[5]  M. Mohty,et al.  18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Michael Lassmann,et al.  First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease , 2016, The Journal of Nuclear Medicine.

[7]  A. Palumbo,et al.  18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease , 2016, Leukemia.

[8]  A. D. Van den Abbeele,et al.  Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome , 2016, Clinical nuclear medicine.

[9]  H. Einsele,et al.  11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement , 2016, Theranostics.

[10]  C. Nanni,et al.  Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Erich A. Peterson,et al.  High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance , 2015 .

[12]  K. Anderson,et al.  Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma , 2015 .

[13]  D. Dingli,et al.  Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy , 2015, Blood Cancer Journal.

[14]  M. Beksac,et al.  European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications , 2015, Haematologica.

[15]  S. Steinberg,et al.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. , 2015, JAMA oncology.

[16]  C. Nanni,et al.  PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma , 2015, Clinical Cancer Research.

[17]  I. Ak,et al.  Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT , 2015, Annals of Hematology.

[18]  D. Hose,et al.  18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate , 2015, Clinical nuclear medicine.

[19]  R. Fanin,et al.  The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  S. Rajkumar,et al.  Smoldering multiple myeloma. , 2015, Blood.

[21]  A. Buck,et al.  11 C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma , 2015 .

[22]  Jian Hou,et al.  Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Ronald Boellaard,et al.  The engagement of FDG PET/CT image quality and harmonized quantification: from competitive to complementary , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  F. Dammacco,et al.  18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders , 2015, Clinical and Experimental Medicine.

[25]  B. Pégourié,et al.  Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial , 2014 .

[26]  M. Beksac,et al.  Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values , 2014 .

[27]  S. Jagannath,et al.  State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. , 2014, European journal of radiology.

[28]  K. Ishiwata,et al.  Comparison of 11C-4′-thiothymidine, 11C-methionine, and 18F-FDG PET/CT for the detection of active lesions of multiple myeloma , 2014, Annals of Nuclear Medicine.

[29]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[30]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Buck,et al.  18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. , 2014 .

[32]  Sirong Chen,et al.  11C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with 18F-FDG PET/CT , 2014, The Journal of Nuclear Medicine.

[33]  D. Huglo,et al.  Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma , 2014, Clinical Cancer Research.

[34]  R. Hustinx,et al.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma , 2014, Haematologica.

[35]  Jun Zhang,et al.  A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease--which is best? , 2014, Asian Pacific journal of cancer prevention : APJCP.

[36]  Su Jin Lee,et al.  Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients , 2013, Acta Haematologica.

[37]  P. Sonneveld,et al.  Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review , 2013, British journal of haematology.

[38]  B. Barlogie,et al.  Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. , 2013, Blood.

[39]  V. Ambrosini,et al.  The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients , 2013, Clinical nuclear medicine.

[40]  B. Barlogie,et al.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data , 2013, Haematologica.

[41]  T. Yen,et al.  11C-Acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  T. Derlin,et al.  Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation , 2013, European Radiology.

[43]  C. Nanni,et al.  Contrast enhanced MRI and ¹⁸F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease. , 2012, European journal of radiology.

[44]  Michele Larobina,et al.  Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma , 2012, The Journal of Nuclear Medicine.

[45]  E. Zamagni,et al.  The role of imaging techniques in the management of multiple myeloma , 2012, British journal of haematology.

[46]  B. Barlogie,et al.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.

[47]  Ji-An Liang,et al.  FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma: A Systematic Review and Meta-analysis , 2012, Clinical nuclear medicine.

[48]  G. Treglia,et al.  The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Evaluating the Response to Treatment in Patients with Multiple Myeloma , 2012, International journal of molecular imaging.

[49]  Cyrus Chargari,et al.  Place of modern imaging modalities for solitary plasmacytoma: toward improved primary staging and treatment monitoring. , 2012, Critical reviews in oncology/hematology.

[50]  Otto S Hoekstra,et al.  18F‐fluoro‐deoxyglucose positron emission tomography in assessment of myeloma‐related bone disease: A systematic review , 2012, Cancer.

[51]  T. Derlin,et al.  18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  R. Fanin,et al.  Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. , 2011, Blood.

[53]  L. Kostakoglu,et al.  Combining FDG‐PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma * , 2011, European journal of haematology.

[54]  M. Ünlü,et al.  Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[55]  G. Çeti̇n,et al.  The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma , 2011, Skeletal Radiology.

[56]  B. Barlogie,et al.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.

[57]  Ludwig G Strauss,et al.  Prediction of Progression-Free Survival in Patients With Multiple Myeloma Following Anthracycline-Based Chemotherapy Based on Dynamic FDG-PET , 2009, Clinical nuclear medicine.

[58]  M. M. Mac Manus,et al.  Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. , 2009, International journal of radiation oncology, biology, physics.

[59]  R. Boellaard.  Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[60]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[61]  S. Eustace,et al.  Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. , 2009, AJR. American journal of roentgenology.

[62]  R. Coleman,et al.  Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry , 2008, Journal of Nuclear Medicine.

[63]  P. Moreau,et al.  FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma , 2008, Haematologica.

[64]  V. Ambrosini,et al.  18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. , 2008, In vivo.

[65]  M. Yun,et al.  Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma , 2008, Acta radiologica.

[66]  M. Salvatore,et al.  18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma , 2008, Journal of Nuclear Medicine.

[67]  V. Ambrosini,et al.  11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma , 2007, World journal of surgical oncology.

[68]  Gerhard Glatting,et al.  Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience. , 2007, Radiology.

[69]  R. Fanin,et al.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.

[70]  E. Vellenga,et al.  18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[71]  B. Line,et al.  Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma , 2006, Skeletal Radiology.

[72]  C. Nanni,et al.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[73]  E Terpos,et al.  Myeloma bone disease: pathophysiology and management. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  Gary Caputo,et al.  Value of FDG PET in the assessment of patients with multiple myeloma. , 2005, AJR. American journal of roentgenology.

[75]  A. Waxman,et al.  Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[76]  J. Cox,et al.  Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. , 1998, International journal of radiation oncology, biology, physics.

[77]  M. Dimopoulos,et al.  Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.